FdaApplication
BLA 125557
Identifiers
- fda_app_no: BLA125557
Properties
| Property | Value |
|---|---|
| applicant_name | Amgen Inc. |
| application_type | BLA |
| approval_date | 2014-12-03 |
Revenue by product
BLINCYTO
| Period | Revenue |
|---|---|
| Q2 2026 | $472.0M |
| Q1 2026 | $415.0M |
| Q4 2025 | $413.0M |
| Q3 2025 | $392.0M |
| Q2 2025 | $384.0M |
| Q1 2025 | $370.0M |
| Q4 2024 | $381.0M |
| Q3 2024 | $327.0M |
| Q2 2024 | $264.0M |
| Q1 2024 | $244.0M |
| Q4 2023 | $241.0M |
| Q3 2023 | $220.0M |
| Q2 2023 | $206.0M |
| Q1 2023 | $194.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| BLINCYTO | BLINATUMOMAB | 35MCG | For Injection |
1 product